Cargando…
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and...
Autores principales: | Kuo, Tsun-Yung, Lin, Meei-Yun, Coffman, Robert L., Campbell, John D., Traquina, Paula, Lin, Yi-Jiun, Liu, Luke Tzu-Chi, Cheng, Jinyi, Wu, Yu-Chi, Wu, Chung-Chin, Tang, Wei-Hsuan, Huang, Chung-Guei, Tsao, Kuo-Chien, Chen, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676267/ https://www.ncbi.nlm.nih.gov/pubmed/33208827 http://dx.doi.org/10.1038/s41598-020-77077-z |
Ejemplares similares
-
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge
por: Lien, Chia-En, et al.
Publicado: (2021) -
Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
por: Lien, Chia-En, et al.
Publicado: (2021) -
Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )
por: Kuo, Tsun-Yung, et al.
Publicado: (2022) -
Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants
por: Liu, Haitao, et al.
Publicado: (2021) -
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC—COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
por: Hsieh, Szu-Min, et al.
Publicado: (2021)